How to Buy Cormedix Stock
Cormedix Inc
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally.
Cormedix stock last closed at $7.41, down 1.46% from the previous day, and has decreased 38.53% in one year. It has underperformed other stocks in the Biotechnology industry by 0.27 percentage points. Cormedix stock is currently +20.98% from its 52-week low of $6.13, and -50.47% from its 52-week high of $14.96.
There are currently 78.45M CRMD shares outstanding. The market capitalization of CRMD is $581.33M. In the last 24 hours, 615,000 CRMD shares were traded.
How to Buy Cormedix Stock
Not sure how to invest in Cormedix stock? Here's how.
- Choose where to buy Cormedix stock: You need to pick an online brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you determine where to buy Cormedix stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Pick your method of payment and add your details.
- Evaluate Cormedix stock: The Cormedix ticker symbol is CRMD. Is Cormedix stock a good investment? Should you buy shares of CRMD? How do CRMD's underlying business fundamentals look? Do top analysts think Cormedix is a good buy? Why has CRMD's stock price moved recently? (Hint: Our stock market research tools can help you decide if CRMD is a good stock to buy).
- Place your CRMD purchase: Decide if you will purchase CRMD shares at the current market price or use a limit order to buy CRMD shares at a specific price.
- Get updates on your CRMD investment: Create a watchlist to keep tabs on your new investment in Cormedix stock.
Step 1: Choose where to buy Cormedix stock
You will need a brokerage account to access the NASDAQ market and buy CRMD stock.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global markets: From Technology to Real Estate, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the best brokerage, it's time to fill out some personal info so you are able to invest in CRMD stock today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to create a new trading account.
- Send your information by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've filled out your info on stock apps to use, you can securely and quickly fund your account:
Check out this video walkthrough for more details transferring money into your new investment account.
Step 4: Evaluate Cormedix stock
Once you have identified the best place to buy Cormedix stock, it's important to evaluate their stock prior to investing, so you actually wrap your head around the risk and opportunity.
Cormedix quick stats
Cormedix Due Diligence Checks
WallStreetZen was designed to help everyday investors perform better fundamental analysis in less time.
You can see all of the due diligence checks on CRMD's stock page.
How is CRMD stock valued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge CRMD's intrinsic value.
Using relative valuations measures:
- CRMD may be undervalued based on its P/E ratio of 3.19x, relative to Biotechnology industry P/E ratio of 14.89x
- CRMD may be undervalued based on its P/B ratio of 1.33x, relative to Biotechnology industry P/B ratio of 5.31x
You can access additional valuation analysis on CRMD's stock here.
A quick look at CRMD Financials
Positive Financial Indicators:
- There are more short-term assets than long-term liabilities on the CRMD balance sheet.
- CRMD earnings of $187.79M is not sufficient to cover its interest payments.
- There are more short-term assets than short-term liabilities on the CRMD balance sheet.
- CRMD profit margin has gone up from 20.8% to 45.2% in the past year.
- CRMD's operating cash flow of $197.69M allows it to safely service it's debt of $144.89M.
Negative Financial Indicators:
- Total CRMD debt is higher than 5 years ago, relative to shareholder equity.
- CRMD has a relatively high debt to equity ratio of 0.87.
Is Cormedix stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 5 Wall Street analysts who track CRMD, the consensus analyst rating on Cormedix is a Buy
Please keep in mind that analyst ratings are not recommendations, nor are they financial advice.
You can dig deeper into what analysts are projecting on the Cormedix stock forecast page.
CRMD Technical Indicators
CRMD Growth Numbers
Last year, CRMD earnings were $181.01M. In the past one years, CRMD's earnings have increased by 792.31% per year. This was faster than the Biotechnology industry average of 11.14%.
Last year, CRMD revenue was $400.05M. In the last 5 year, CRMD's revenue has gone up by 336.16% per year. This was faster than the Biotechnology industry average of 34.26%.
You can analyze CRMD's earnings and revenue performance here.
Who is buying/selling CRMD?
Over the last 12 months, executives and large shareholders at CRMD have sold more shares than they have bought.
Susan Blum, Chief Financial Officer of CRMD, was the latest CRMD insider to sell. They sold $71,006.09 worth of CRMD shares on Jan 23, 2026.
Get more info about who owns CRMD shares here.
Can I rely on CRMD as an income stream?
No, Cormedix doesn't provide an income stream by paying out dividends.
CRMD Social Trading Data
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your CRMD purchase
You have two main order types:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are mostly fine. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at a particular dollar amount limit, place a limit order.
Click the Open Trade button and your broker will execute your order.
If you need more assistance buying stocks on eToro, click the how to video below:
Step 6: Get updates on your CRMD investment
Now that you own some CRMD shares, you'll want to stay up-to-date on your new stock purchase.
Add CRMD to a watchlist to track the most important metrics related to your CRMD stock.
CRMD Feed
How to Buy Stock in Cormedix
To reiterate, here are the 6 steps for buying Cormedix stock:
- Choose where to buy Cormedix stock
- Sign up for your brokerage account
- Deposit funds into your brokerage account
- Evaluate Cormedix stock
- Place your CRMD purchase
- Get updates on your CRMD investment
If you need a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you want to keep an eye on your new investment in Cormedix, click the button below.
Related Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.